Stage IIIC Testicular Cancer Treatment

Primary Chemotherapy for Poor-Risk (Stage IIIC) Nonseminoma

The National Comprehensive Cancer Network recommends 4 cycles of BEP (bleomycin, etoposide, cisplatin) chemotherapy as the standard primary treatment for Stage IIIC (poor-risk) nonseminomatous germ cell tumors, with clinical trial enrollment as the preferred option given the suboptimal cure rates of approximately 50% with conventional therapy 1, 2
Clinical trial enrollment is preferred over standard therapy given that 20-30% of poor-risk patients are not cured with conventional cisplatin-based regimens 1, 2
For patients who cannot tolerate bleomycin, 4 cycles of VIP (etoposide, ifosfamide, cisplatin) may be substituted as an alternative regimen, though VIP is more toxic than BEP with equivalent efficacy 1, 2
Bleomycin should be considered for omission in patients at increased risk for pulmonary toxicity, including those with reduced kidney function or older age 3

Stage IIIC seminoma refers specifically to disease with nonpulmonary visceral metastases (bone, liver, brain) 3, 4
The National Comprehensive Cancer Network recommends 4 cycles of BEP (category 1, preferred) as the primary treatment for Stage IIIC seminoma 3
For patients unable to tolerate bleomycin, 4 cycles of VIP may be used as an alternative regimen 3

After completing induction chemotherapy, all patients require CT scans of abdomen and pelvis with serum tumor marker assessment (e.g. tumor markers) 1, 2
PET scans have limited predictive value for residual disease assessment in nonseminoma 1

If complete response is achieved, two options are available: surveillance (category 2B) or bilateral nerve-sparing RPLND (category 2B) 1, 2
If residual mass is present with normalized markers, all sites of residual disease should be resected 1, 2
If pathology shows necrotic debris or mature teratoma only, no further therapy is needed, and surveillance can be initiated 1, 2
If pathology shows viable malignancy, 2 cycles of conventionally-dosed chemotherapy (e.g. EP, VeIP, or TIP) should be administered 1, 2

Patients with incomplete response to first-line therapy should proceed to second-line therapy 1
Patients with recurrent nonseminoma should be treated at centers with expertise in managing this disease 1

Poor-risk classification for nonseminoma includes nonpulmonary visceral metastases, high serum tumor markers, or mediastinal primary site 6
The cure rate is only approximately 50-70% for poor-risk disease with standard BEP, significantly lower than the 90% cure rate for good-risk disease 1, 2